αStock Quant AI
ResearchAPI
  1. Home
  2. /
  3. Research
  4. /
  5. MRNA

Equity Research · Friday, September 25, 2026

MRNASellUnderweight

MRNA Stock Analysis for September 2026

Moderna, Inc. Common Stock


Price at Analysis

$194.82
1Y Target$95.00-51.2%
3Y Target$120.00-38.4%

1Y Price Target

$95.00

-51.2%

vs current price

Technical Setup

RSI 75 / bullish MACD

Support context: $22.28. Resistance context: $195.71.

Valuation Snapshot

P/E N/A (negative earnings) / P/S ~45x (minimal sales vs cap)

Market cap $72.70B; revenue ~$1.0-2.0B TTM (Q2'26 $145M, Q1'26 $389M, down 12.52% YoY).

Risk Watch

Extreme overvaluation after squeeze

Up 402% YTD, 127% in one month, 774% off $22.28 low to $72.7B cap. Rothschild downgrade to Sell, target $81 (-58% downside), Wall Street avg ~$45 when stock at $80. Valuation implies flawless oncology execution years early.

01 · Summary

Executive Summary

Moderna has staged one of the most violent biotech repricings in recent history, up ~400% YTD to $194.82, just 0.5% below its $195.71 52-week high from a $22.28 low. The driver is real: individualized neoantigen therapy intismeran autogene with Merck's Keytruda met primary and key secondary endpoints in Phase III INTerpath-001 melanoma, plus FDA approval of mFLUSIVA flu vaccine on Aug 5 after a 9-0 advisory vote. The market has repriced Moderna from a declining COVID company to a platform oncology company overnight. The repricing has overshot fundamentals. Q2 2026 revenue was only $145M (+2% YoY) with a $782M net loss ($-1.97 EPS), Q1 lost $1.34B including a $950M settlement, cash fell to $6.9B, and trailing revenue is down 12.5% YoY with EPS down 166% YoY. A $72.7B market cap on <$1B annualized product sales is >70-120x sales for a still loss-making vaccine business plus a pre-commercial personalized cancer asset. Rothschild & Co Redburn downgraded to Sell with an $81 target, Wall Street's average target sat near $45 when the stock was at $80, and shorts have suffered ~$5.5B in losses on a 177% surge — classic short-squeeze fuel, not earnings compounding. With RSI 75.1 and parabolic volume, risk/reward is now skewed sharply down on a 12-month view.

02 · Scenario Modeling

Price Targets

1Y Base Target

$95.00-51.2%

3Y Base Target

$120.00-38.4%

1-Year scenario price targets · Dashed line = current price

02 · Scenario Modeling

Scenario Analysis

Scenario1Y Target1Y Growth3Y Target3Y Growth
↑↑Hyper Bull
$380.00+95.1%$550.00+182.3%
↑Bull
$260.00+33.5%$340.00+74.5%
→Neutral
$190.00-2.5%$220.00+12.9%
↓Bear
$95.00-51.2%$120.00-38.4%
↓↓Hyper Bear
$45.00-76.9%$60.00-69.2%
↑↑Hyper Bull
1Y$380
3Y$550
1Y %+95.1%
3Y %+182.3%
↑Bull
1Y$260
3Y$340
1Y %+33.5%
3Y %+74.5%
→Neutral
1Y$190
3Y$220
1Y %-2.5%
3Y %+12.9%
↓Bear
1Y$95
3Y$120
1Y %-51.2%
3Y %-38.4%
↓↓Hyper Bear
1Y$45
3Y$60
1Y %-76.9%
3Y %-69.2%
Hyper Bull — Intismeran files in 2027 with priority review, shows overall survival benefit, expands rapidly to lung/bladder with Merck funding, while mFLUSIVA captures 20%+ US flu share. Revenue re-accelerates to $5B+ by 2028 with path to profitability, justifying 10x+ sales platform multiple. Short squeeze fully converts to long-only ownership.
Bull — Melanoma data holds on full publication, FDA grants breakthrough designation, flu launch beats low expectations for 2026/27 season. Losses narrow faster, cash burn stabilizes, pipeline readouts sustain 30%+ premium to biotech peers. Momentum persists despite high RSI.
Neutral — Oncology promise is real but already priced; stock consolidates high-tight flag near $190 as investors wait for full Phase III data, regulatory filing timeline, and flu commercial proof. Revenue stays lumpy $1-2B, losses continue, valuation compresses modestly but platform floor holds.
Bear — Squeeze exhausts and gravity returns: $72B on ~$600M annualized product sales cannot hold without near-term earnings. Flu is commoditized with no 2026 guide, personalized vaccine faces manufacturing/cost and profit-split hurdles, cash burn forces raise. Stock retraces 50%+ toward Rothschild $81 and pre-surge levels, with only partial 3-year recovery as oncology slowly advances.
Hyper Bear — Full data shows marginal benefit vs Keytruda alone, FDA requires additional trial, flu uptake disappoints amid competition and vaccine hesitancy/policy headwinds. Cash burn accelerates, dilutive raise at lower prices, COVID base keeps eroding. Returns to Wall Street's prior $45 average target area.

03 · Fundamentals

Key Financial Metrics

Earnings Per Share (EPS)
$-1.97 Q2'26 vs $-2.13 prior year
Revenue
~$1.0-2.0B TTM (Q2'26 $145M, Q1'26 $389M, down 12.52% YoY)
P/E Ratio
N/A (negative earnings)
P/S Ratio
~45x (minimal sales vs cap)
Market Cap
$72.70B
Net Income
Net loss $782M Q2'26; $1.34B loss Q1'26
Dividend Yield
0.00%
Short Interest
Elevated - ~$5.5B short losses on 177% surge, squeeze-driven
52-Week Low
$22.28
52-Week High
$195.71

02 · Scenario Modeling

Technical Overview

Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.

RSI (14)

75.1

Momentum Stack

1M +22.7% / 3M +226.1%

Volatility Regime

75.2% 20D vol

Regression Fit

+89.2% vs trend

Close20D MA50D MA200D MABollinger (20, 2σ)Regression channel centerline

Drawdown Curve

Distance from rolling peak, useful for regime stress and recovery speed.

+0.0%

Trend Regime

bullish

Price > 50D > 200D

Composite Signal

bullish

Bullish (+3)

Mean Reversion

bullish

+2.54 sigma

Breakout Status

bullish

Above 20D high

Range Percentile

bullish

99th pct

Volume Impulse

neutral

1.01x 20D avg

Quant Dashboard

A compact read on trend persistence, stretch, realized risk, and breakout behavior.

1M Return
+22.7%
6M Return
+263.9%
1Y Return
N/A
ATR (14)
$11.95
20D Vol
75.2%
60D Vol
228.2%
Regression R²
0.59
Price Z-Score
+2.54
52W High
$195.71
52W Low
$22.28
Range Position
99th pct
Latest Volume
16.6M

04 · Research

Micro Analysis

Pipeline validation is genuine but commercial scale, economics, and cash burn do not support a $72.7B valuation today.

Revenue base vs valuation disconnect

Q2 2026 revenue $145M (+2% YoY) driven by partnerships/stand-ready manufacturing, Q1 $389M vs $108M prior year. TTM product sales ~$1-2B and down 12.52% YoY per Zacks data. At $72.7B market cap, Moderna trades at ~40-70x TTM sales and infinite P/E (loss-making). Q2 loss $782M improved only 5% YoY, loss per share $-1.97 vs $-2.13. No operating leverage yet.

Intismeran Phase III win is real but early for $50B+ of value creation

Intismeran + Keytruda improved recurrence-free survival and distant metastasis-free survival in melanoma Phase III INTerpath-001, lifting stock ~150% intraday Aug 19. Morningstar raised fair value. However asset is partnered with Merck (economics split), personalized manufacturing is complex/costly, and filing/commercial launch is years away with 9 additional Phase II/III studies in lung, bladder, renal and others still to read out. Blockbuster potential exists but no near-term earnings.

Vaccine portfolio offers breadth, not growth

mFLUSIVA flu approved Aug 5 and shown more effective than marketed flu vaccines, plus EU approvals for mCOMBRIAX (flu+COVID combo) and progress on mRESVIA (RSV). Yet management is not guiding for 2026 contribution from mRNA-1010/mFLUSIVA, citing mid-year approval and competitive dynamics. Flu/RSV/COVID are low-price, seasonal, competitive markets dominated by GSK, Pfizer, Sanofi. Diversification helps narrative, not 2026-2027 P&L.

Cash burn and balance sheet runway

Cash and investments $6.9B end-Q2 vs $7.5B end-Q1, implying ~$600M quarterly burn before pipeline expansion for oncology commercial scale. Q1 net loss $1.34B included $950M litigation settlement. With 4,700 employees and 25 clinical candidates plus commercial-scale manufacturing already built, opex remains elevated. 2-3 years runway at current burn without dilution, partnership milestones, or cost cuts.

Earnings trajectory still negative

Zacks notes EPS down 166.67% YoY, Hold rank, modest +1.42% estimate revision and +26.1% upward revision over 30 days off a deeply negative base. Improving loss per share estimates for 2026-2027 cited by bulls, but still losses with no path to 2028 profitability except under aggressive oncology/vaccine uptake assumptions per Finterra analysis.

04 · Research

Macro Analysis

Biotech beta is supportive but Moderna is now an outlier, vulnerable to rate, rotation, and vaccine-policy risks.

Biotech funding recovery helps sentiment, not all mRNA

1H 2026 venture funding $9.1B (highest since 2022) and 38 acquisitions (7-year high pace) support biotech multiples. However reports note mRNA post-pandemic second act still unproven, with Moderna as the tension point. Sector tailwind lifts boats but does not justify 774% off lows vs peers.

Rates and rotation double-edged

Fed hiked in Sept 2026; BioSpace notes biotech can withstand due to M&A/catalysts, Robeco notes pharma trading at discount to market after AI hyperscaler chase. Lower-duration profitable biotechs benefit most from rate-cut hopes (TickerSpark). Cash-burning, long-duration Moderna with $72B cap is most vulnerable if yields stay high.

US vaccine policy uncertainty

Morningstar and company commentary flag declining COVID demand and uncertain US vaccine policy environment forcing cash budgeting and prioritization. Flu/COVID combo and RSV commercial execution face pricing, recommendation, and uptake risk.

Short squeeze and positioning overhang

Bloomberg/Seeking Alpha: 177% surge caused ~$5-5.5B in short losses in painful squeeze. High-tight flag on low volume suggests institutional accumulation per technicians, but also crowded momentum. Once squeeze exhausts, prior shorts + profit-taking + $81 sell-side targets create air pocket. Volume 16.6M and VWAP $188.40 vs close $194.82 shows late-day chase.

Healthcare quality-growth revival excludes parabolic names

Robeco quality-growth revival favors profitable pharma/tools at discount. Moderna screens opposite: unprofitable, extreme multiple, RSI 75.1 overbought. Rotation may favor Merck, GSK, Sanofi over MRNA on risk-adjusted basis.

05 · Growth

Untapped Revenue Opportunities

Intismeran autogene in melanoma and expansion

high

Phase III melanoma success with Keytruda opens adjuvant melanoma (~large addressable market, high price) plus 9 ongoing Phase II/III in NSCLC, bladder, renal and other solid tumors. Personalized cancer vaccine could be multi-billion if manufacturing scales and Merck co-commercializes globally.

mFLUSIVA next-gen flu vaccine

medium

FDA approved Aug 5, superior efficacy vs marketed flu vaccines in trials, unanimous 9-0 panel vote. Launch for 2026/2027 season targets 50+ population. Flu market is $5-7B globally; even modest share is material vs $145M quarterly base.

Combination and next-gen vaccines

medium

mCOMBRIAX flu+COVID combo first EU approval, mRESVIA RSV, updated COVID boosters, plus international stand-ready manufacturing revenue ($145M Q2 included this). Portfolio approach smooths seasonality and leverages mRNA platform.

06 · Catalysts

Headwinds & Tailwinds

↓ Headwinds

Extreme overvaluation after squeeze

high

Up 402% YTD, 127% in one month, 774% off $22.28 low to $72.7B cap. Rothschild downgrade to Sell, target $81 (-58% downside), Wall Street avg ~$45 when stock at $80. Valuation implies flawless oncology execution years early.

Overbought technicals and squeeze exhaustion

high

RSI 75.1 overbought, trading at 99.5% of 52-week high, high-tight flag breakout on heavy 16.6M volume. Prior $5.5B short losses suggest marginal buyer was short cover. Pullback risk high once momentum stalls; days-to-cover unwind complete.

Persistent losses and dilution risk

high

Net losses $782M Q2, $1.34B Q1, cash down $600M QoQ to $6.9B. No dividend, no buyback capacity. Further oncology trials + commercial build will require cash; equity raise at high price possible but dilutive if stock falls, or partnerships on worse terms.

Personalized oncology scalability

medium

Individualized neoantigen therapy requires tumor sequencing, bespoke manufacturing, rapid turnaround and Keytruda combination. Cost, logistics, reimbursement and competition from BioNTech, Gritstone, and cell therapies could limit margins and uptake vs off-the-shelf drugs.

↑ Tailwinds

Platform validation de-risks mRNA beyond COVID

high

Phase III T-cell priming success plus 9-0 flu vote and mFLUSIVA approval prove mRNA works in oncology and flu, supporting 25-candidate pipeline across infectious disease, oncology, CV and rare disease.

Merck partnership and commercial scale ready

medium

Merck co-development/commercial muscle for intismeran, manufacturing already at commercial scale per Sept 14 Morgan Stanley conference, supporting global trials and future launches without greenfield build.

Improving estimate revisions and momentum

medium

Loss of $1.97 beat $-2.13 prior year, consensus revised up 26.1% in 30 days, VGM Score B, Cramer 'finally investable', breakout price action. Positive sentiment can sustain premium while data flows.

07 · TL;DR

Analysis Summary

Ticker
MRNA
Company
Moderna, Inc. Common Stock
Analysis Date
2026-09-25
Price at Analysis
$194.82
Rating
Sell
1Y Price Target
$95.00
3Y Price Target
$120.00
Market Cap
$72.70B
P/E Ratio
N/A (negative earnings)

This analysis was generated on 2026-09-25 when MRNA was trading at $194.82. The base-case 1-year price target is $95.00 (-51.2% implied return). Scenario range: $45.00 (hyper bear) to $380.00 (hyper bull).

Disclaimer: This report is generated by an AI model and is for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Past performance is not indicative of future results. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Keep Reading

More Research

INFQSell

Infleqtion, Inc.

2026-09-25

GLNDSell

Greenland Energy Company Common Stock

2026-09-25

ARMSell

Arm Holdings plc American Depositary Shares

2026-09-25

Stock Quant AI
SupportBuilt by John Leonardo · Not financial advice.